🇺🇸 FDA
Pipeline program

Linvoseltamab

R5458-ONC-2245

Phase 3 small_molecule active

Quick answer

Linvoseltamab for Relapsed Refractory Multiple Myeloma (RRMM) is a Phase 3 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 2 ClinicalTrials.gov record(s).

Program details

Company
REGENERON PHARMACEUTICALS, INC.
Indication
Relapsed Refractory Multiple Myeloma (RRMM)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials